OBJECTIVE: To determine whether men with rheumatoid arthritis (RA) are more likely to achieve remission compared to women. METHODS: RA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) cohort between October 2001 and January 2010 were selected for the present analyses. Detailed clinical, demographic, and drug utilization data were available at enrollment (baseline) and at subsequent followup visits. We examined the influence of sex on the Clinical Disease Activity Index remission score (≤2.8) using sustained remission or point remission as the primary outcome measure in multivariate stepwise logistic regression models. We stratified the data by RA duration at baseline (≤2 years or >2 years) to investigate whether RA duration had differential effects on remission in men and women. RESULTS: A total of 10,299 RA patients (2,406 men and 7,893 women) were available for this study. In both early and established RA, women had more severe disease at baseline with worse disease activity measures, modified Health Assessment Questionnaire disability index score, pain on a visual analog scale, and depression. Women were also more likely to have been treated with disease-modifying antirheumatic drugs and anti-tumor necrosis factor therapy compared to men. In the regression models, male sex was associated with sustained remission in early RA (odds ratio [OR] 1.38, 95% confidence interval [95% CI] 1.07-1.78, P = 0.01), but not in established RA. However, for point remission, an inverse association was observed with male sex in established RA (OR 0.65, 95% CI 0.48-0.87, P = 0.005) and not in early RA. CONCLUSION: Within the large real-life CORRONA cohort of RA patients, men were more likely to achieve sustained remission compared to women in early RA, although not in established RA.
OBJECTIVE: To determine whether men with rheumatoid arthritis (RA) are more likely to achieve remission compared to women. METHODS: RA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) cohort between October 2001 and January 2010 were selected for the present analyses. Detailed clinical, demographic, and drug utilization data were available at enrollment (baseline) and at subsequent followup visits. We examined the influence of sex on the Clinical Disease Activity Index remission score (≤2.8) using sustained remission or point remission as the primary outcome measure in multivariate stepwise logistic regression models. We stratified the data by RA duration at baseline (≤2 years or >2 years) to investigate whether RA duration had differential effects on remission in men and women. RESULTS: A total of 10,299 RA patients (2,406 men and 7,893 women) were available for this study. In both early and established RA, women had more severe disease at baseline with worse disease activity measures, modified Health Assessment Questionnaire disability index score, pain on a visual analog scale, and depression. Women were also more likely to have been treated with disease-modifying antirheumatic drugs and anti-tumor necrosis factor therapy compared to men. In the regression models, male sex was associated with sustained remission in early RA (odds ratio [OR] 1.38, 95% confidence interval [95% CI] 1.07-1.78, P = 0.01), but not in established RA. However, for point remission, an inverse association was observed with male sex in established RA (OR 0.65, 95% CI 0.48-0.87, P = 0.005) and not in early RA. CONCLUSION: Within the large real-life CORRONA cohort of RA patients, men were more likely to achieve sustained remission compared to women in early RA, although not in established RA.
Authors: Damini Jawaheer; Paul Maranian; Grace Park; Maureen Lahiff; Sogol S Amjadi; Harold E Paulus Journal: J Rheumatol Date: 2010-10-01 Impact factor: 4.666
Authors: Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald F van Vollenhoven Journal: Ann Rheum Dis Date: 2010-12-13 Impact factor: 19.103
Authors: Samantha L Hider; Wajeeha Tanveer; Ann Brownfield; Derek L Mattey; Jon C Packham Journal: Rheumatology (Oxford) Date: 2009-07-16 Impact factor: 7.580
Authors: Tuulikki Sokka; Sergio Toloza; Maurizio Cutolo; Hannu Kautiainen; Heidi Makinen; Feride Gogus; Vlado Skakic; Humeira Badsha; Tõnu Peets; Asta Baranauskaite; Pál Géher; Ilona Ujfalussy; Fotini N Skopouli; Maria Mavrommati; Rieke Alten; Christof Pohl; Jean Sibilia; Andrea Stancati; Fausto Salaffi; Wojciech Romanowski; Danuta Zarowny-Wierzbinska; Dan Henrohn; Barry Bresnihan; Patricia Minnock; Lene Surland Knudsen; Johannes Wg Jacobs; Jaime Calvo-Alen; Juris Lazovskis; Geraldo da Rocha Castelar Pinheiro; Dmitry Karateev; Daina Andersone; Sylejman Rexhepi; Yusuf Yazici; Theodore Pincus Journal: Arthritis Res Ther Date: 2009-01-14 Impact factor: 5.156
Authors: Carson Maynard; Ted R Mikuls; Grant W Cannon; Bryant R England; Philip G Conaghan; Mikkel Østergaard; Daniel G Baker; Gail Kerr; Michael D George; Jennifer L Barton; Joshua F Baker Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Enriqueta Vallejo-Yagüe; Julia N Pfund; Theresa Burkard; Carole Clair; Raphael Micheroli; Burkhard Möller; Axel Finckh; Andrea M Burden Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Cynthia Nourisson; Martin Soubrier; Aurélien Mulliez; Athan Baillet; Thomas Bardin; Alain Cantagrel; Bernard Combe; Maxime Dougados; René-Marc Flipo; Thierry Schaeverbeke; Jean Sibilia; Olivier Vittecoq; Philippe Ravaud; Jacques-Eric Gottenberg; Xavier Mariette; Anne Tournadre Journal: RMD Open Date: 2017-11-01
Authors: Robert J Moots; Anthony Sebba; William Rigby; Andrew Ostor; Benjamin Porter-Brown; Francis Donaldson; Sophie Dimonaco; Andrea Rubbert-Roth; Ronald van Vollenhoven; Mark C Genovese Journal: Rheumatology (Oxford) Date: 2017-04-01 Impact factor: 7.580
Authors: Jonathan Aldridge; Jayesh M Pandya; Linda Meurs; Kerstin Andersson; Inger Nordström; Elke Theander; Anna-Carin Lundell; Anna Rudin Journal: Arthritis Res Ther Date: 2018-07-20 Impact factor: 5.156